Leveraging its lawyers’ experience as government officials in regulatory and policy agencies, Hogan Lovells International LLP's Greater China life sciences practice is consistently sought out to for complex regulatory issues. The team advises at all stages of life sciences products, from initial clinical trials to off-patent strategy, business development and defence-side litigation The team also advises on new technology-driven areas, such as digital health, AI, gene therapy and regenerative medicine. On the mainland, Lu Zhou advises life sciences and healthcare clients on cross-border transactions; and Calvin Ding represents companies (and their board committees) in relation to corruption, conflicts of interest, trade compliance and cybersecurity incidents. Jessie Xie's practice covers regulatory work and commercial contracts in the pharmaceutical, medical devices, healthcare, food, and cosmetics sectors.
Legal 500 redaktioneller Kommentar

Auszeichnungen

Mandantenzufriedenheit

Kernmandanten

  • Sinopharm Commonwealth Company
  • Merck Sharp & Dohme
  • Aspen

Highlight-Mandate

  • Advised Sinopharm Commonwealth Company on making a pre-conditional proposal to privatise China Traditional Chinese Medicine Holdings Co.
  • Acted for Merck Sharp & Dohme in cross-border litigation concerning rights to the MERCK trade mark and trade name.

Anwält*innen

Führende Partner*innen

Die stärksten Partner*innen ihres Praxisbereichs, die eine führende Rolle in signifikanten Mandaten einnehmen und weitreichende Anerkennung unter Wettbewerbern und Mandanten genießen.

Lu Zhou

Führende Associates

Führende Associates sind regelmäßig an zentralen Mandaten des Teams beteiligt und erhalten positives Feedback von Wettbewerbern oder Mandanten.

Praxisleitung

Lu Zhou; Calvin Ding

Weitere Kernanwält*innen

Jessie Xie; Adrian Emch; Roy Zou; Andrew McGinty; Sammy Li; Tony Mou